Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ornithine phenylacetate - Ocera Therapeutics

Drug Profile

Ornithine phenylacetate - Ocera Therapeutics

Alternative Names: L-Ornithine phenylacetate; MNK 6106; MNK-6105; OCR-002; OP; Ornithine hydrochloride/sodium phenylacetate; Sodium phenylacetate/ornithine hydrochloride; UCL-L1V

Latest Information Update: 28 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University College London
  • Developer Ocera Therapeutics
  • Class Basic amino acids; Diamino amino acids; Esters; Hepatoprotectants; Neuroprotectants; Phenylacetates; Small molecules
  • Mechanism of Action Aminohydrolase modulators; Ammonia scavengers; NF-kappa B modulators; Nitric oxide synthase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic encephalopathy; Liver failure
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Hepatic encephalopathy
  • Phase II Liver cirrhosis; Liver failure
  • Preclinical Non-alcoholic fatty liver disease

Most Recent Events

  • 01 Dec 2018 Phase-II clinical trials in Liver cirrhosis in USA (PO) (NCT03712280)
  • 01 Dec 2018 Mallinckrodt initiates a phase IIa trial for Hepatic encephalopathy in USA (PO, Tablet) (NCT03712280)
  • 28 Oct 2018 No recent reports of development identified for phase-I development in Hepatic-encephalopathy(Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top